Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1994520 | 0.83 | PIK3CA (0.44) | KMT2AMEN1ATMLMNAPIK3CD | |
| SCHEMBL20037847 | 0.83 | PIK3CD (0.42) | KMT2AMEN1ATMPIK3CD | |
| SCHEMBL18390616 | 0.81 | TRPV6 (0.48) | PIK3CD | |
| SCHEMBL610954 | 0.79 | KMT2A (0.67) | KMT2AMEN1ATMALDH1A1CHRNA1 | |
| SCHEMBL29814598 | 0.79 | KMT2A (0.67) | KMT2AMEN1ATMALDH1A1CHRNA1 | |
| SCHEMBL3401709 | 0.78 | LMNA (0.60) | ALDH1A1LMNAPIK3CD | |
| SCHEMBL12642576 | 0.78 | PIK3CD (0.47) | KMT2AMEN1LMNAL3MBTL1PIK3CD | |
| SCHEMBL1977991 | 0.78 | KMT2A (0.51) | KMT2AMEN1ATMALDH1A1CHRNA1 | |
| SCHEMBL221818 | 0.77 | MC4R (0.58) | KMT2AMEN1ALDH1A1LMNAPIK3CD | |
| SCHEMBL21161033 | 0.76 | KMT2A (0.67) | KMT2AMEN1ATMALDH1A1CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2026-05-28 | — | — | US | disclosed |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2024-02-08 | — | — | US | disclosed |
| US-20210253578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2021-08-19 | — | — | US | disclosed |
| US-20210253578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | ASTEX THERAPEUTICS LTD. (GB) | 2021-08-19 | — | — | US | disclosed |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2018-06-07 | — | — | US | disclosed |
| US-20170183352-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| US-20170183352-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| US-20170183352-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2017-06-29 | — | — | US | disclosed |
| US-8415355-B2 | Pyrrolopyrimidine compounds and their uses | NOVARTIS AG (CH) | 2013-04-09 | — | — | US | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2011-06-23 | — | — | US | disclosed |
| EP-2331547-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | Novartis AG (CH) | 2011-06-15 | — | — | EP | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | NOVARTIS AG | 2010-04-29 | — | — | US | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020675-A1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260146042-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK9, CDK6, CDK7 | KMT2A 915/4885MEN1 2512/4885ATM 364/4885 |
| US-20110152244-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | KMT2A 1553/4885MEN1 3341/4885ATM 353/4885 |
| US-20170183352-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | KMT2A 1553/4885MEN1 3341/4885ATM 353/4885 |
| US-20240043428-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | KMT2A 1553/4885MEN1 3341/4885ATM 353/4885 |
| US-20180155351-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | KMT2A 1553/4885MEN1 3341/4885ATM 353/4885 |
| US-20210253578-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | KMT2A 1553/4885MEN1 3341/4885ATM 353/4885 |
| US-20100105653-A1 | PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USES | CDK6, CDK8, CDK7 | KMT2A 1553/4885MEN1 3341/4885ATM 353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.